These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8126248)

  • 81. Recombinant human erythropoietin: physiology, pathophysiology of anemia in renal failure, and economic aspects related to dosing.
    Besarab A
    Am J Nephrol; 1990; 10 Suppl 2():2-6. PubMed ID: 2260613
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Recombinant human erythropoietin (rHuEPO) in the treatment of anaemia of chronic renal failure.
    Desai JD; Shah BV
    J Assoc Physicians India; 1991 Jun; 39(6):483-5. PubMed ID: 1938855
    [No Abstract]   [Full Text] [Related]  

  • 83. Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy.
    Majdan M; Ksiazek A; Kozioł M; Spasiewicz D; Swatowski A; Solski J
    Nephron; 1996; 73(3):425-9. PubMed ID: 8832602
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment.
    Hamada Y; Kono TN; Moriguchi Y; Higuchi M; Fukagawa M
    Nephrol Dial Transplant; 2008 Jun; 23(6):1886-91. PubMed ID: 18174266
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin.
    Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
    Br J Haematol; 1995 Jan; 89(1):17-23. PubMed ID: 7833259
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
    Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Erythropoietin and cardiovascular risk.
    Allegra V; Martimbianco L; Mengozzi G; Vasile A
    Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Anaemia management in cardio renal disease.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    J Ren Care; 2010 May; 36 Suppl 1():86-96. PubMed ID: 20586904
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Personal experience with the use of human recombinant erythropoietin in the treatment of anemia in children with chronic renal insufficiency].
    Podracká L; Sasinka M; Roland R; Böör A
    Cesk Pediatr; 1992 May; 47(5):268-71. PubMed ID: 1638649
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin.
    Zirkman DM; Zeigler ZR; Fraley DS; Bruns FJ; Adler S
    Am J Kidney Dis; 1993 Jan; 21(1):31-7. PubMed ID: 8418623
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Erythropoietin treatment in haemodialysis patients with iron overload.
    el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB
    Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Erythropoietin treatment in children with renal failure.
    Van Damme-Lombaerts R; Herman J
    Pediatr Nephrol; 1999 Feb; 13(2):148-52. PubMed ID: 10229005
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.
    Locatelli F; Olivares J; Walker R; Wilkie M; Jenkins B; Dewey C; Gray SJ;
    Kidney Int; 2001 Aug; 60(2):741-7. PubMed ID: 11473657
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.
    Stenvinkel P; Bárány P
    Nephrol Dial Transplant; 2002; 17 Suppl 5():32-7. PubMed ID: 12091605
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Recombinant human erythropoietin.
    Schwenk MH; Halstenson CE
    DICP; 1989; 23(7-8):528-36. PubMed ID: 2669369
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parameters.
    Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
    Eur J Haematol; 1994 Nov; 53(5):265-70. PubMed ID: 7813706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.